American Heart Association 2018 Scientific Sessions.

Abstract

We report on sessions on the dapagliflozin effect on cardiovascular events; angiotensin receptor-neprilysin inhibition for acute decompensated heart failure; rivaroxaban's effect on thromboembolic events with heart failure, sinus rhythm, and coronary disease; trial results on the withdrawal of pharmacological heart failure therapy in recovered dilated cardiomyopathy; and more from AHA's November meeting.